The first class antispasmodic candidate to reach the clinical stage was published in a prestigious Life Science Journal. cell. Candidate MPH-220 could represent new hope for millions of patients suffering from spasticity.
Chronic muscle spasticity after nervous system defects such as stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, and painful low back pain affects more than 10% of the population and has socioeconomic costs. It’s about US $ 500 billion. Currently, there is no satisfactory cure to help these suffering people, which creates an immense medical need for a new generation of antispasmodics.
András Málnási-Csizmadia, co-founder of Motorpharma Ltd. and professor at Eötvös Loránd University in Hungary, is leading the development of first-in-class drug candidates co-sponsored by Printnet Ltd. MPH-220 is due to muscle contraction, potentially taking one tablet daily. In contrast, current treatments are less effective and cause a variety of side effects because they act indirectly through the nervous system.
Stroke survivors suffering from intolerable symptoms of spasticity receive a desperate email asking if they can participate in our study. We are working hard to accelerate the development of MPH-220 to alleviate the chronic spasticity of these people. “
András Málnási-Professor Csizmadia
The mechanism of action of MPH-220 and preclinical studies have recently been published. cell.. Dr. Máté Gyimesi, CSO of Motorpharma Ltd., emphasizes: “The scientific challenge was to develop a compound that would distinguish between these contractile motor proteins, skeletal muscle myosin and myocardial myosin. This function of MPH-220 makes it more specific and safe.”
Professor James Spudich, co-founder of Cytokinetics, MyoKardia, and Kainomyx, said that all companies developing drugs that target cytoskeletal components are also very excited about MPH-220 as the next-generation muscle relaxant. I am. “Cytokinetics and MyoKardia show that cardiac myosin is very effective, and both companies have potential drugs that act on cardiac myosin in late-stage clinical trials, but no skeletal myosin effectors have been reported. Hmm.
Motorpharma Ltd. is currently developing MPH-220, a specific inhibitor of skeletal myosin. This is a drug candidate that has the potential to reduce the daily painful spasticity of about 10% of the population suffering from back pain and nerve damage-related disorders, “says Professor Spudich. , Former Chairman of the Biochemistry Division of Stanford University School of Medicine, Lasker Award Winner.
Drug development specifically targeting myosin can be seen in the full cash acquisition of MyoKardia by Bristol Myers Squibb last week for $ 13.1 billion in hopes of selling experimental cardiac drugs targeting cardiac myosin. In addition, it is becoming a prominent field. This business activity illustrates the demand of emerging biotechnology companies such as Myocardia and Motorpharma.
“Muscle research-focused motorpharma is ready to offer MPH-220, a candidate antispasmodic drug with a new mechanism of action. Treatment of spasticity is an unmet need and post-stroke It puts a lot of strain on the condition and diseases such as chronic low back pain, “said the professor. Istvan Bitter, former head of CNS for Eli Lilly Co’s regional hub.
Eotvos Loland University (ELTE), Faculty of Science
Gyimesi, M. , et al. (2020) Single-residue variability of skeletal muscle myosin allows direct and selective drug targeting of spasticity and muscle stiffness. cell. doi.org/10.1016/j.cell.2020.08.050.